Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (3)

Trial Status

Recruiting1
Active Not Recruiting1
Unknown1
Terminated1

Clinical Trials (4)

Showing 4 of 4 trials
NCT02180867Phase 2Active Not Recruiting

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT04925609Phase 1Recruiting

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

NCT02465528Phase 2Terminated

Ceritinib Rare Indications Study in ALK+ Tumors

NCT03874273Phase 2UnknownPrimary

Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

Showing all 4 trials

Research Network

Activity Timeline